Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OUS Approvals Analysis: Slow Finish To 2016, But Still Ahead Of 2015

Executive Summary

2016 finished with just two more non-US medical device approvals than 2015; December was by far the slowest month of the year for approvals from outside the US with just 11.

You may also be interested in...



Medtronic Misses Mid-Year Mark With 'Disappointing' 3% Growth

The medtech giant says slow sales in its cardiovascular and diabetes businesses while it awaits important product approvals were a drag on its overall revenues during the second fiscal quarter of 2017.

HiberGene's Under-An-Hour Meningitis Test Hits Europe

Emerging Irish IVD company HiberGene Diagnostics has just CE marked HG Meningococcus, a molecular diagnostic test for bacterial meningitis that can detect Neisseria meningitidis in cerebrospinal fluid, whole blood and via a nasopharyngeal swab in less than one hour. The company is set to launch the test in Europe with distribution agreements in place for Ireland, Germany, Austria, Spain, Turkey and Poland.

News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More

Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel